PE20050347A1 - Derivados de pirrolopirimidina - Google Patents
Derivados de pirrolopirimidinaInfo
- Publication number
- PE20050347A1 PE20050347A1 PE2004000821A PE2004000821A PE20050347A1 PE 20050347 A1 PE20050347 A1 PE 20050347A1 PE 2004000821 A PE2004000821 A PE 2004000821A PE 2004000821 A PE2004000821 A PE 2004000821A PE 20050347 A1 PE20050347 A1 PE 20050347A1
- Authority
- PE
- Peru
- Prior art keywords
- link
- pirrol
- group
- links
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
DERIVADOS DE PIRROLOPIRIMIDINA DE FORMULA I DONDE X ES O, S; A1 ES UN ENLACE UNICO, ALQUILO C1-C6 QUE LIGA UN NITROGENO UNIDO A A1 CON A2 EN EL MISMO O DIFERENTES CARBONOS; A2 ES UN ENLACE O UN GRUPO QUE LIGA A1 CON G1 EN FORMA DE A1-(C=O)-G1, A1-C(=O)-O-G1, A1-O-G1, ENTRE OTROS; G1 ES UN ENLACE O UN GRUPO DIVALENTE QUE SE OBTIENE POR REMOCION DE 2 HIDROGENOS A PARTIR DE CUALQUIERA DE LOS HIDROCARBUROS AROMATICOS OPCIONALMENTE SUSTITUIDOS QUE TIENEN 6-14 CARBONOS, ENTRE OTROS; A3 ES ALQUILO C1-C6; A4 ES UN ENLACE O UN GRUPO QUE LIGA A3 CON G2 EN FORMA DE A3-C(=O)-G2, A3-C(=O)-O-G2; G2 ES H, ALQUILO C1-C10, UN CICLOALQUILO C3-C8, ENTRE OTROS; A5 ES UN ENLACE O NR201; R201 ES H O ALQUILO C1-C4 ; R2 ES H, F, CL, BR, I, ENTRE OTROS; A6 ES UN ENLACE UNICO, O UN GRUPO QUE LIGA R3 CON UN CARBONO DEL ANILLO PIRROL, EN FORMA DE R3-C(=O)-PIRROL, R3-C(=O)-O-PIRROL, R3-O-C(=O)-PIRROL, ENTRE OTROS; R3 ES H, F, CL, BR, I, NITRO, GRUPO HIDROCARBONADO ALIFATICO SATURADO C1-C10 OPCIONALMENTE SUSTITUIDO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 5-{2-(T-BUTOXI)CARBONILAMINO}ETIL}-6-(3-CLORO(2-TIENIL))-4-OXO-3-HIDROPIRROLO [3,2-D]PIRIMIDIN-7-CARBOXAMIDA; 5-{2-[(T-BUTOXI)CARBONILAMINO]ETIL}-6-CICLOPROPIL-4-OXO-3-HIDROPIRROLO[3,2-D]PIRIMIDIN-7-CARBOXAMIDA; N-{2-[7-AMINO-6-(3-CLORO(2-TIENIL))-4-OXO(3-HIDROPIRROLO[3,2-D]PIRIMIDIN-5-IL}ETIL}(T-BUTOXI) CARBOXIAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE GLUCOGENO SINTASA QUINASA-3 (GSK-3)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003301022 | 2003-08-26 | ||
JP2004100022 | 2004-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20050347A1 true PE20050347A1 (es) | 2005-05-04 |
Family
ID=34220733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004000821A PE20050347A1 (es) | 2003-08-26 | 2004-08-26 | Derivados de pirrolopirimidina |
Country Status (15)
Country | Link |
---|---|
US (1) | US20050153992A1 (es) |
EP (2) | EP1661897B1 (es) |
JP (2) | JPWO2005019218A1 (es) |
KR (1) | KR101098808B1 (es) |
CN (1) | CN1871240B (es) |
AR (1) | AR045507A1 (es) |
AU (1) | AU2004266975B2 (es) |
BR (1) | BRPI0413821A (es) |
CA (1) | CA2536887C (es) |
MX (1) | MXPA06002001A (es) |
NO (1) | NO20060538L (es) |
PE (1) | PE20050347A1 (es) |
RU (1) | RU2358975C2 (es) |
TW (2) | TW200519116A (es) |
WO (2) | WO2005019218A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7205308B2 (en) * | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
WO2005019218A1 (ja) * | 2003-08-26 | 2005-03-03 | Teijin Pharma Limited | ピロロピリミジンチオン誘導体 |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
RU2437868C2 (ru) * | 2006-11-06 | 2011-12-27 | Сагами Кемикал Рисерч Сентр | Реакционный реагент для трифторметилирования |
US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
EA201270566A1 (ru) | 2009-10-16 | 2012-11-30 | Риб-Экс Фармасьютикалз, Инк. | Противомикробные соединения и способы их получения и применения |
WO2011047323A2 (en) | 2009-10-16 | 2011-04-21 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compounds and methods of making and using the same |
EA201270568A1 (ru) | 2009-10-16 | 2012-11-30 | Риб-Экс Фармасьютикалз, Инк. | Антимикробные композиции и способы их получения и применения |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CN102329325B (zh) * | 2010-07-07 | 2013-11-27 | 中国科学院广州生物医药与健康研究院 | 吡咯并嘧啶酮类dpp-iv抑制剂 |
CN103476258B (zh) | 2011-02-25 | 2017-04-26 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
SG194489A1 (en) * | 2011-04-15 | 2013-12-30 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
CN103929961A (zh) * | 2011-06-20 | 2014-07-16 | 美国阿尔茨海默病研究所公司 | 化合物及其治疗应用 |
EP2880028B1 (en) | 2012-08-02 | 2020-09-30 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CA2898482A1 (en) | 2013-02-22 | 2014-08-28 | Linda L. Brockunier | Antidiabetic bicyclic compounds |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
CN105814057B (zh) * | 2013-07-31 | 2019-05-03 | 默克专利有限公司 | 用作btk抑制剂的嘧啶、吡啶和吡嗪及其用途 |
AU2014315050A1 (en) | 2013-09-09 | 2016-03-24 | Melinta Therapeutics, Inc. | Antimicrobial compunds and methods of making and using the same |
JP2016529325A (ja) | 2013-09-09 | 2016-09-23 | メリンタ セラピューティクス,インコーポレイテッド | 抗微生物化合物ならびにそれの製造方法および使用方法 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP2913333A1 (en) | 2014-02-27 | 2015-09-02 | Laboratoire Biodim | 3H-thieno[3,4]pyrimidin-4-one and pyrrolopyrimidone as gram-positive antibacterial agents |
AR103297A1 (es) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
US9938300B2 (en) | 2015-02-05 | 2018-04-10 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
US9840491B2 (en) | 2015-02-05 | 2017-12-12 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
JP2018504431A (ja) | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス,インコーポレイテッド | ユビキチン特異的プロテアーゼ7阻害物質としてのチエノピリミジノン |
JP2018507881A (ja) | 2015-03-11 | 2018-03-22 | メリンタ セラピューティクス,インコーポレイテッド | 抗微生物化合物ならびにこれらを作製および使用する方法 |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
AR111874A1 (es) | 2017-05-18 | 2019-08-28 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
PL3625222T3 (pl) | 2017-05-18 | 2021-12-27 | Idorsia Pharmaceuticals Ltd | Pochodne fenylu jako modulatory receptora pge2 |
ES2929309T3 (es) | 2017-05-18 | 2022-11-28 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor PGE2 |
ES2894124T3 (es) * | 2017-05-18 | 2022-02-11 | Idorsia Pharmaceuticals Ltd | Derivados de indol N-sustituidos |
CN110612299A (zh) | 2017-05-18 | 2019-12-24 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的嘧啶衍生物 |
PE20220573A1 (es) * | 2019-05-13 | 2022-04-20 | Relay Therapeutics Inc | Inhibidores de fgfr y metodos de uso de los mismos |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0071227B1 (en) * | 1981-07-31 | 1987-11-11 | Sloan-Kettering Institute For Cancer Research | Anti-leukemic beta-glycosyl c-nucleosides |
US4584369A (en) * | 1981-07-31 | 1986-04-22 | Sloan-Kettering Institute For Cancer Research | Anti-leukemic beta-glycosyl C-nucleosides |
DE58902899D1 (de) * | 1988-12-14 | 1993-01-14 | Ciba Geigy Ag | 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer. |
CA2051012C (en) * | 1990-09-14 | 2002-04-02 | David R. Borcherding | Carbocyclic adenosine analogs useful as immunosupressants |
AU642526B2 (en) * | 1990-09-14 | 1993-10-21 | Marion Merrell Dow Inc. | Method of immunosuppression using cyclopentenyl substituted nucleoside analogs and compositions thereof |
WO1993021187A1 (en) * | 1992-04-21 | 1993-10-28 | Biocryst Pharmaceuticals, Inc. | 7-DISUBSTITUTED-METHYL-4-OXO-3H^_,5H^_-PYRROLO[3,2-d^_]PYRIMIDINE AND PHARMACEUTICAL USES AND COMPOSITIONS CONTAINING THE SAME |
AU6855594A (en) * | 1993-06-30 | 1995-01-24 | Biocryst Pharmaceuticals, Inc. | 9-deazahypoxanthines as pnp inhibitors |
AU716993B2 (en) * | 1995-05-12 | 2000-03-16 | Neurogen Corporation | Novel deazapurine derivatives; a new class of CRF1 specific ligands |
WO1997049706A1 (en) * | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
US5985848A (en) * | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
DE10009000A1 (de) * | 2000-02-25 | 2001-08-30 | Basf Ag | Verfahren zur Herstellung substituierter Indole |
WO2002018371A1 (en) * | 2000-08-29 | 2002-03-07 | Industrial Research Limited | Nucleoside metabolism inhibitors |
US6458799B1 (en) * | 2000-08-31 | 2002-10-01 | Biocryst Pharmaceuticals, Inc. | Deazaguanine analog, preparation thereof and use thereof |
AU2002305205A1 (en) * | 2001-04-20 | 2002-11-05 | Jingrong Cao | 9-deazaguanine derivatives as inhibitors of gsk-3 |
US6660719B2 (en) * | 2001-12-17 | 2003-12-09 | Biocryst Pharmaceuticals Inc. | Inhibiting T-Cell proliferation |
TW200306191A (en) * | 2002-02-22 | 2003-11-16 | Teijin Ltd | Pyrrolopyrimidine derivatives |
AU2003233667A1 (en) * | 2002-05-23 | 2003-12-12 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
DE60336734D1 (de) * | 2002-08-21 | 2011-05-26 | Ind Res Ltd | Sidasen |
WO2005019218A1 (ja) * | 2003-08-26 | 2005-03-03 | Teijin Pharma Limited | ピロロピリミジンチオン誘導体 |
-
2004
- 2004-08-26 WO PCT/JP2004/012690 patent/WO2005019218A1/ja active Application Filing
- 2004-08-26 AR ARP040103069A patent/AR045507A1/es unknown
- 2004-08-26 BR BRPI0413821-0A patent/BRPI0413821A/pt not_active IP Right Cessation
- 2004-08-26 EP EP04772648.4A patent/EP1661897B1/en not_active Not-in-force
- 2004-08-26 AU AU2004266975A patent/AU2004266975B2/en not_active Ceased
- 2004-08-26 TW TW093125681A patent/TW200519116A/zh unknown
- 2004-08-26 EP EP04772646A patent/EP1661896A4/en not_active Withdrawn
- 2004-08-26 JP JP2005513397A patent/JPWO2005019218A1/ja not_active Withdrawn
- 2004-08-26 TW TW093125571A patent/TW200509938A/zh unknown
- 2004-08-26 RU RU2006109503/04A patent/RU2358975C2/ru not_active IP Right Cessation
- 2004-08-26 CN CN2004800314501A patent/CN1871240B/zh not_active Expired - Fee Related
- 2004-08-26 US US10/928,600 patent/US20050153992A1/en not_active Abandoned
- 2004-08-26 JP JP2005513398A patent/JP4570566B2/ja not_active Expired - Fee Related
- 2004-08-26 CA CA2536887A patent/CA2536887C/en not_active Expired - Fee Related
- 2004-08-26 WO PCT/JP2004/012692 patent/WO2005019219A1/ja active Application Filing
- 2004-08-26 PE PE2004000821A patent/PE20050347A1/es not_active Application Discontinuation
- 2004-08-26 MX MXPA06002001A patent/MXPA06002001A/es unknown
-
2006
- 2006-02-02 NO NO20060538A patent/NO20060538L/no not_active Application Discontinuation
- 2006-02-23 KR KR1020067003712A patent/KR101098808B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2004266975B2 (en) | 2009-11-12 |
CN1871240B (zh) | 2012-11-07 |
WO2005019219A1 (ja) | 2005-03-03 |
CA2536887A1 (en) | 2005-03-03 |
RU2358975C2 (ru) | 2009-06-20 |
JPWO2005019219A1 (ja) | 2006-10-19 |
MXPA06002001A (es) | 2006-06-20 |
JPWO2005019218A1 (ja) | 2006-10-19 |
CN1871240A (zh) | 2006-11-29 |
EP1661897A1 (en) | 2006-05-31 |
WO2005019218A1 (ja) | 2005-03-03 |
NO20060538L (no) | 2006-03-24 |
EP1661896A4 (en) | 2008-07-16 |
AU2004266975A1 (en) | 2005-03-03 |
EP1661897B1 (en) | 2013-12-04 |
AR045507A1 (es) | 2005-11-02 |
EP1661896A1 (en) | 2006-05-31 |
TW200519116A (en) | 2005-06-16 |
TW200509938A (en) | 2005-03-16 |
JP4570566B2 (ja) | 2010-10-27 |
EP1661897A4 (en) | 2008-11-19 |
US20050153992A1 (en) | 2005-07-14 |
KR20060118416A (ko) | 2006-11-23 |
RU2006109503A (ru) | 2007-10-10 |
BRPI0413821A (pt) | 2006-10-24 |
KR101098808B1 (ko) | 2011-12-26 |
CA2536887C (en) | 2012-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20050347A1 (es) | Derivados de pirrolopirimidina | |
RU2504544C2 (ru) | 8-замещенные производные изохинолина и их применение | |
CO5540280A2 (es) | Derivados aromaticos de acido dicarboxilico | |
AR112789A2 (es) | COMPUESTOS INHIBIDORES DE DOPAMINA-b-HIDROXILASA | |
EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
PE20020469A1 (es) | Policiclicos nucleotidicos como inhibidores de xantina fosfodiesterasa v | |
DOP2001000170A (es) | Derivados de tiofeno utiles como agentes anticancesoros | |
AR063643A1 (es) | Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas | |
CO6180449A2 (es) | Quinazolinonas y naftiridinonas que incluyen un grupo n-(bifenil-4-ilmetil-n-(piperidin-4-il)acetamida sustituida, utiles para el tratamiento de aterosclerosis | |
PE20070805A1 (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
PE20061295A1 (es) | Derivados de acetileno | |
RS52771B (en) | CARBAMOIL-CYCLOHEXANE DERIVATIVES (TIO) AS AN D3 / D2 RECEPTOR ANTAGONISTS | |
PE20050130A1 (es) | Compuestos organicos | |
AR038481A1 (es) | Derivados de dihidrobenzodiazepin-2-ona iii para el tratamiento de desordenes neurologicos | |
ECSP066968A (es) | Compuestos de metil-aril o heteroaril-amida sustituida | |
PE20061335A1 (es) | Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c | |
TW200604407A (en) | Optical brightening of substrates for ink jet printing | |
PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
AR065093A1 (es) | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos | |
TW200612920A (en) | Novel imidazolidine derivatives | |
AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
RU2008106251A (ru) | В-лактамилзамещенные аналоги фенилаланина, цистейна и серина в качестве антагонистов вазопрессина | |
ECSP088084A (es) | Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |